After laparotomy, treating large incisional hernias (width >= 10cm) proves challenging due to the progressive retraction of lateral abdominal muscles and the separation of rectus muscles. This width is a significant risk factor for repair failure and recurrence. High rates of severe postoperative morbidity, up to 50%, are reported, linked to dissection extent, increased muscular tension, and abdominal pressure. Reconstructing normal anatomy by bringing muscles together may be impossible, leading to the use of complex procedures like component separation techniques (CST), involving large aponeurotomy for muscle relaxation. Intramuscular injection of botulinum toxin A (BTA) induces reversible flaccid paralysis, with potential benefits in hernia closure, known as "chemical CST." Retrospective studies suggest reduced muscle retraction and facilitated closure without specific morbidity. Prehabilitation with BTA aims to reduce surgical morbidity compared to repair and CST. The prospective evaluation of BTA's clinical benefits, including reduced postoperative morbidity, pain, successful abdominal closure, and decreased IH recurrence risk, is lacking. A prospective randomized double-blind placebo-controlled trial is proposed to demonstrate BTA's efficacy. The hypothesis is that BTA injection before IH repair is more effective than a placebo in reducing postoperative morbimortality. Secondary expectations include a significant reduction in complete closure of the abdominal wall without CST.

开始日期2025-01-17

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT06604832

/ Recruiting临床1期IIT

Effects of PrabotulinumtoxinA-xvfs on Facial Skin Quality, Fine Wrinkles, and Texture

The goal of this split-face clinical trial is to test the efficacy of microtox in improving facial skin quality, fine wrinkles, and texture. Participants will:
* be randomly assigned to Group A (which will receive 20 units of neuromodulator on the left side of the forehead and a placebo saline treatment on the right side) or Group B (which will receive 20 units of neuromodulator on the left side of the forehead and 20 units of a different neuromodulator brand on the right side as a comparator)
* have one treatment session at week 0, and two live assessment visits at weeks 2 and 12
* have their pictures taken at each visit to track progress

开始日期2024-09-03

申办/合作机构

Evolus, Inc.

NCT06788158

/ Active, not recruiting临床1期IIT

Clinical Effects of the Intralesional Application of Incobotulinum Toxin vs Corticosteroid in Patients With Plantar Fascitis

Objectives: To evaluate the clinical effects of intralesional application of incobotulinum toxin vs corticosteroid in patients with plantar fasciitis .
Material and methods: Prospective, experimental, randomized, controlled clinical study; the population will be recruited in the outpatient clinic of the rehabilitation service meeting the inclusion criteria, two randomized study groups will be formed: GROUP A: Patients who accept intralesional infiltration with incobotulinum toxin . GROUP B: Patients who accept intralesional infiltration with dexamethasone.
Both groups will be assessed before application, at 1 month, at 2 and 4 months post intervention. The visual analogue scale (VAS), the American Orthopaedic Foot and Ankle Society (AOFAS) scale and the Foot and Ankle Disability Index (FADI) will be used to assess pain, foot functionality, functional disability index in activities of daily living, in physical activity and measurement of the dorsiflexion arch in 2 visits at the beginning of diagnosis and at 4 months, collecting the variables and establishing a hypothesis analysis to accept or discard normality criteria of the same with tendency and its significance in relation to p <0.05 to establish contrast of the results with parametric or non-parametric variables according to whether or not the hypothesis of normality is discarded.

开始日期2024-09-01

申办/合作机构

Instituto Mexicano del Seguro Social

100 项与 A型肉毒毒素 (Biotecon) 相关的临床结果

登录后查看更多信息

100 项与 A型肉毒毒素 (Biotecon) 相关的转化医学

登录后查看更多信息

100 项与 A型肉毒毒素 (Biotecon) 相关的专利（医药）

登录后查看更多信息

1,119

项与 A型肉毒毒素 (Biotecon) 相关的文献（医药）

2025-12-01·Techniques in Coloproctology

Urge fecal incontinence: are intramural rectal injections of botulinum toxin a long-term treatment option?

Article

作者: Baumstarck, Karine ; Vitton, Véronique ; Onana Ndong, Philippe

BACKGROUND AND AIMS:

Unsuccessful first-line conservative treatments for managing fecal incontinence (FI) lead to considering predominantly invasive options, posing challenges in terms of cost and patient acceptance of benefit/risk ratio. Recent data from a prospective randomized study have highlighted intramural rectal botulinum toxin (BoNT/A) injection as a promising minimally invasive alternative for urge FI, demonstrating efficacy at 3 months but lacking long-term evidence. This study aimed to evaluate the sustained efficacy and injection frequency of intramural rectal BoNT/A injection in the treatment of urge FI.

METHODS:

This retrospective monocentric study enrolled all patients who underwent intramural rectal BoNT/A injection for urge FI after failed conservative therapy or sacral neuromodulation (SNM). Injections were administered during sigmoidoscopy, delivering 200 U of BoNT/A at 10 circumferentially distributed sites. Treatment effectiveness was assessed using the Cleveland clinic incontinence score (CCS) and a visual analog scale (VAS) to measure the severity of discomfort related to episodes of fecal urgency, with reinjection performed upon symptom recurrence.

RESULTS:

In total, 41 patients (34 females) were included, with a median follow-up of 24.9 (range 3.2-70.3) months. Overall, 11 patients had previously failed sacral nerve stimulation. Significant reductions were observed in the CCS (median 11 versus 7, p = 0.001) and VAS symptoms (median 4, range 0-5 versus median 2, range 0-5, p = 0.001). In total, 22 patients (53%) experienced a reduction in the CCS by over 50%. The median interval between intramural rectal BoNT/A injections was 9.8 months (range 5.3-47.9 months).

CONCLUSIONS:

This study provides the first evidence of the sustained efficacy of intramural rectal BoNT/A injection for urge FI. Further investigations are warranted to refine patient selection and reinjection criteria, evaluate socioeconomic impacts, and compare rectal BoNT/A injection with other therapeutic modalities.

2025-03-06·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Sequential use of botulinum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity

Article

作者: Akulov, M.A. ; Krasavina, D.A. ; Valiev, V.K. ; Orlova, O.R. ; Iakovleva, P.N. ; Ivanov, D.O.

A clinical case of consistent use of botulinum toxin type A (BTA) and azoximer bovhialuronidase (BA) in a 69-year-old patient who suffered an ischemic stroke (II) with right-sided hemiparesis is presented. BTA (incobotulotoxin) was injected under ultrasound control (ultrasound) into the muscles of the target pathological patterns at a dose of 500 units. After 3 weeks, under the control of ultrasound navigation, BA was injected into the 2 most fibrotic shoulder muscles at a dose of 3.000 IU (1.500 IU each). The effectiveness of therapy was monitored using a modified Ashworth scale (MAS), goniometry, and electromyography. A decrease in the severity of the leading pattern of spasticity of the muscles of the upper extremity (on the MAS scale) after injection of BTA was found. After consistent application of BA, a distinct change in the structure of muscle tissue and a decrease in tone in spastic muscles were recorded. The results obtained confirm the safety of botulinum therapy and the good tolerability and efficacy of Xeomin in a patient with spasticity with contracture formation after AI. The introduction of ASTHMA after botulinum therapy makes it possible to increase the elasticity of spastic muscles by reducing the severity of fibrous changes and improving motor function.

2025-03-01·OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY

Successful Treatment of Severe, Poorly Controlled Benign Essential Blepharospasm with DaxibotulinumtoxinA

Article

作者: Kikkawa, Don O. ; Sargsyan, Suzan ; Dib El Jalbout, Nahia ; Korn, Bobby S. ; Liu, Catherine Y. ; Al-Sharif, Eman ; Shoji, Marissa K.

Benign essential blepharospasm is a focal dystonia characterized by involuntary contractions of the orbicularis oculi. Botulinum toxin type A injections are often first-line treatment, but patients may experience refractory symptoms or decreased response over time. DaxibotulinumtoxinA, a novel botulinum toxin type A product, has shown promise in cervical dystonia and facial rhytids but has not been previously reported for benign essential blepharospasm treatment. This case highlights a 57-year-old male with severe, poorly controlled benign essential blepharospasm despite high-dose injections of onabotulinumtoxinA and incobotulinumtoxinA. He subsequently received 100 units of daxibotulinumtoxinA in the same periorbital injection pattern with subjective faster onset, extended duration of effect, and improved symptom management compared to previous treatments. Notably, the patient experienced 50% to 75% efficacy retention at 3 months postinjection, significantly better than his response to other botulinum toxin type A products. This case suggests that daxibotulinumtoxinA may be an effective treatment for benign essential blepharospasm including patients experiencing poor symptom control with other botulinum toxin type A products.

项与 A型肉毒毒素 (Biotecon) 相关的新闻（医药）

2025-01-06

·赞Med

直面“帕”痛|帕金森病疼痛相关文献解读

点击上方“蓝字”关注我们吧！疼痛是帕金森病（PD）患者最常见的非运动症状，同时也是PD最早的症状之一，其患病率约为40-85%，尽管它严重影响着患者的生活质量，但仍经常被低估甚至漏诊，并且患者通常只能得到非系统性的治疗，据报道，大约有50%的PD疼痛患者从未接受过任何镇痛治疗。疼痛的病因和病理生理学特征复杂多样，关于治疗的建议也十分有限。目前的研究表明，除了多巴胺能系统外，5-羟色胺能、去甲肾上腺素能、谷氨酸能和GABA能途径可能也参与其中。此外，除PD本身及其他相关继发疾病（如骨关节炎）导致的疼痛外，PD的运动或非运动症状（如运动迟缓或抑郁）本身就会放大疼痛。因此，我们试图总结概述PD患者中疼痛的分类和治疗，为临床更好的疼痛管理提供建议1-2。 1.疼痛的分类 Wasner和Deuschl提出的分类方法在临床实践中使用较为广泛，他们将PD中的疼痛分为四个层次，结合了之前分类的特点和慢性疼痛分类的原则（图1）。图1：PD疼痛的分类另一种常用的分类方法是Ford的方法，它将疼痛分为五类：肌肉骨骼疼痛、肌张力障碍性疼痛、神经病理性/根性疼痛、中枢性/原发性疼痛以及静坐不能性疼痛。 2.疼痛的治疗肌肉骨骼疼痛是PD患者最常提及的类型，通常源于肌肉或关节的痉挛和疼痛，沙非胺已被证明可改善PD患者的肌肉骨骼疼痛3。此外，深部脑刺激（DBS）、非甾体抗炎药（NSAID）或其他镇痛药、关节内注射皮质类固醇或手术也可根据临床情况进行选择。肌张力障碍是一种不受控制且剧烈的肌肉收缩，导致畸形和姿势异常。肌张力障碍是多巴胺能治疗的并发症。因此推荐优化治疗以稳定多巴胺血浆水平，比如使用单胺氧化酶B（MAO-B）或儿茶酚胺-O-甲基转移酶（COMT）抑制剂，可减少白天和夜间的疼痛性运动波动以及早晨运动迟缓。在基于两项大型随机对照试验（RCT）汇总数据的事后分析中4-5，沙非胺作为左旋多巴治疗的附加疗法，与安慰剂相比，减少了疼痛药物的使用（约24%），并在PDQ-39量表的三个子项中有两项（肌肉骨骼和神经病理性疼痛）得分显著降低。神经病理性/根性疼痛可能伴有感觉异常（刺痛）和麻木，沿着外周神经或神经根的支配区域分布，一线药物包括三环类抗抑郁药（TCAs）、抗癫痫药（如普瑞巴林和加巴喷丁）以及血清素和去甲肾上腺素再摄取抑制剂（如度洛西汀）。沙非胺也可能对根性疼痛有效3。弱阿片类药物（曲马多）被视为二线药物，而利多卡因或辣椒素贴片仅推荐用于外周神经病变。中枢性疼痛是最难描述的感觉之一，热感、灼烧感、针刺感，甚至刺痛都较为常见，多巴胺能药物在缓解这种疼痛方面并不特别有效。因此，通常使用传统的镇痛药，如阿片类药物、三环类抗抑郁药（TCAs）和氯氮平。大麻素和双侧亚核团深部脑刺激（subthalamic DBS）也可能有效。静坐不能是一种以内心不安和持续的冲动去移动或改变位置为特征的疾病，在病理上与中皮质通路的多巴胺缺乏有关，氯氮平可能在治疗上有所帮助。 3.临床研究现状 2024年1月发表在《Lancet》中的《Medical, surgical, and physical treatments for Parkinson’s disease》对目前帕金森病的治疗进行了系统综述6，其中疼痛部分见表1。表1：PD非运动症状中疼痛的治疗 2021年在日本PD患者中的 2/3 期临床研究的事后分析提示4，沙非胺50mg和100mg降低了PD患者的UPDRS第17项评分，尤其是在关期。中度至重度运动迟缓和早期肌张力障碍患者可能受益于沙非胺的治疗（图2、3）。图2：在关期和开期UPDRS第17项评分从基线到第24周的平均变化*P值与安慰剂相比图3：关期（A）和开期（B）UPDRS第17项评分相对于基线的平均变化 2018年一项研究沙非胺对PD患者慢性疼痛长期（2年）疗效的研究表明5，与安慰剂相比，沙非胺显著改善了PDQ-39中第37项（“痛苦的痉挛或痉挛”，p = 0.0074）和第39项（“令人不快的热或冷”，p = 0.0209）（图4），并显著减少了26.2%伴随疼痛治疗的数量（p = 0.005），且沙非胺组中治疗 2 年后未使用止痛药的患者比例更高（p = 0.0478）（图5）。图4：PDQ-39中第37-39项从基线到第 102 周（2年）的变化图5：第102周（2年）同时使用疼痛治疗的情况 4.总结疼痛对PD患者的生活质量有重大影响，并且常常被临床医生忽视。但导致PD疼痛表现出如此广泛谱系的原因至今未明。其中，运动症状（如肌肉僵硬、姿势障碍、运动波动等）与肌肉骨骼疼痛、肌张力障碍性疼痛和神经性疼痛相关，非运动症状，如自主神经功能障碍、睡眠障碍和情绪障碍，也发挥着重要作用。因此，对疼痛进行分类有助于选择适当的管理策略。疼痛的治疗方案较为复杂，建议进行多学科综合管理，目前在中国上市的甲磺酸沙非胺片无疑为PD患者的疼痛治疗提供新选择，多篇临床研究及系统综述均阐述了其对PD患者疼痛的积极影响，且经过2年研究观察长期有效。希望在日后诊疗中，“帕”痛不再被忽视，早期识别和处理可大大减轻患者残疾，从而改善远期生活质量。参考文献 [1] Cattaneo C, Jost WH. Pain in Parkinson's Disease: Pathophysiology, Classification and Treatment. J Integr Neurosci. 2023 Sep 8;22(5):132. [2] Buhmann C, Kassubek J, Jost WH. Management of Pain in Parkinson's Disease. J Parkinsons Dis. 2020;10(s1):S37-S48. [3]Cattaneo C, Barone P, Bonizzoni E, Sardina M. Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis. Journal of Parkinson’s Disease. 2017; 7: 95–101. [4] Tsuboi Y, Koebis M, Kogo Y, et al. Effects of safinamide adjunct therapy on pain in patients with Parkinson’s disease: post hoc analysis of a Japanese phase 2/3 study. J Neurol Sci 2021; 429: 118070. [5]Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term efficacy of safinamide on Parkinson’s disease chronic pain. Adv Ther 2018; 35: 515–22. [6] Foltynie T, Bruno V, Fox S, Kühn AA, Lindop F, Lees AJ. Medical, surgical, and physical treatments for Parkinson's disease. Lancet. 2024 Jan 20;403(10423):305-324. [7]Bruno V, Freitas ME, Mancini D, Lui JP, Miyasaki J, Fox SH. Botulinum toxin type A for pain in advanced Parkinson’s disease. Can J Neurol Sci 2018; 45: 23–29. [8]Rieu I, Degos B, Castelnovo G, et al. Incobotulinum toxin A in Parkinson’s disease with foot dystonia: a double blind randomized trial. Parkinsonism Relat Disord 2018; 46: 9–15. [9]Iwaki H, Ando R, Tada S, et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson’s disease. J Neurol Sci 2020; 414: 116833 提示：本材料仅供医疗卫生专业人士进行医学科学交流，不用于推广目的。

2024-12-18

·PRNewswire

Persimmon.life Introduces SmartTox® Injectable Treatment Offered at Select Massage Envy Locations

Persimmon.life will provide their medical aesthetic services at select Massage Envy Franchised locations across Arizona and California in early 2025 SCOTTSDALE, Ariz., Dec. 18, 2024 /PRNewswire/ -- Massage Envy, a national leader in skin care and the nation's No. 1 provider of massage in the U.S. collectively across its franchise network, and Persimmon.life, the leader in on-location medical aesthetic treatments, today announced a new initiative in which Persimmon will offer SmartTox® injectable treatments at select Massage Envy franchised locations across Arizona and California in early 2025. "Massage Envy is always looking for strategic relationships with brands that help address consumers' wellness goals. Persimmon's use of Massage Envy locations to provide their medical aesthetic services will not only be convenient, but will also address the needs of the modern skincare consumer," said Todd Schrader, CEO, Massage Envy Franchising. "Massage Envy has been a leader in skin care for over 16 years and looking and feeling your best is at the core of the Massage Envy brand. We are excited that our franchisees are welcoming Persimmon into their Massage Envy franchised locations." Each Persimmon service includes a personalized assessment with a Persimmon Provider, who will review goals, answer questions and explain the treatment. Sessions typically take between 15 and 20 minutes. "Massage Envy is a company that has set the standard for accessible wellness and self-care," said Mark Hadfield, CEO, Persimmon.life. "At Persimmon, we share Massage Envy's commitment to helping people look and feel their best, and we're thrilled that Persimmon will be on-site at select Massage Envy franchised locations to provide high-quality, medically-driven SmartTox® treatments." According to Persimmon.life, SmartTox®, also known as XEOMIN® and IncobotulinumtoxinA or Neurotoxin, is a double-filtered neuromodulator injection that smooths upper facial lines including frown lines, forehead lines and crow's feet without unnecessary proteins. The procedure will be available by appointment only at select Massage Envy California and Arizona franchise locations beginning in early 2025. For more information and to make an appointment, visit the Persimmon website at . About Persimmon Founded in 2021, Persimmon is at the forefront of medical aesthetics, transforming how aesthetic treatments are provided. By partnering with local businesses, Persimmon offers clients unparalleled flexibility and privacy through a growing network of highly skilled, medically-trained injection nurses available at select partnership locations. Guided by a clinical leadership team of expert nurses, Persimmon has established itself as a leader in safety, quality, and care. Their meticulously-designed training and treatment protocols ensure every client experiences top-tier results. With thousands of glowing five-star reviews, Persimmon's reputation speaks to its commitment to excellence and its ability to deliver transformative care in a setting that clients trust and enjoy. For more information, visit or follow @persimmon.life on Instagram, TikTok and Facebook. About Massage Envy Massage Envy, based in Scottsdale, Arizona, is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services and skin care offerings. Massage Envy was founded in 2002 and started offering skin care services in 2008. The brand now has over 1,000 franchise locations in 49 states that have together delivered more than 225 million massages and skin care services. For more information, visit or follow @MassageEnvy on Instagram, X and Facebook. Contact: [email protected] SOURCE Massage Envy WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-12-17

·Business Wire

Health Canada Approves XEOMIN® (incobotulinumtoxinA) for Treatment of Adults with Post-stroke Lower Limb Spasticity in the Ankle and Foot

BURLINGTON, Ontario--( BUSINESS WIRE )-- Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN ® (incobotulinumtoxinA) for the treatment of post-stroke lower limb spasticity involving the ankle and foot in adults. “This approval means that adult patients who have suffered from a stroke and are experiencing lower limb spasticity in the ankle and foot will now have a safe and effective treatment option,” explains Michael Stone, Country Manager, Canada for Merz Therapeutics. “With this label extension, healthcare providers can now utilize XEOMIN to pursue more comprehensive and individually ambitious treatment goals for their patients.” Addressing multiple patterns of spasticity with XEOMIN Strokes are the primary cause of spasticity resulting from damage to the upper motor neuron, producing an abnormal increase in muscle tone. In Canada, 109,000 people annually suffer a stroke 1 , and 25% to 43% of stroke survivors experience spasticity within a year 2 . XEOMIN with the active ingredient incobotulinumtoxinA is injected intramuscularly to reduce the abnormally increased muscle tone. With the new approval, XEOMIN can be administered in up to 600 units for upper and lower limbs combined, enabling qualified healthcare professionals in Canada to treat both regions together or individually, adjusting the dosage depending on patient requirements and mobility goals. The safety findings were similar to previous adult studies and in line with the known safety profile of XEOMIN. The most common adverse reactions affecting ≥1% of patients were nasopharyngitis, pharyngitis, tinea pedis, muscular weakness, epilepsy, fall, eczema, dehydration, and blurred vision. “Foot and ankle spasticity are the most common posture problems seen in the lower limb in adult patients following a stroke. They typically present with an equinovarus deformity, which refers to the foot turning downwards and inwards in these limbs," said Professor Lalith Satkunam, Glenrose Rehabilitation Hospital, Edmonton, Alberta. "Lower limb spasticity can limit ambulation and impede on patients' daily lives, so this latest approval for XEOMIN provides healthcare professionals, like me, the ability to comprehensively treat multiple areas of spasticity.” “The ability to simultaneously treat both upper and lower limb post-stroke spasticity in adults with botulinum toxin using a combined total dose of 600 units makes it an essential tool in our treatment arsenal,” shared Dr. Jehane Dagher, Institut de réadaptation Gingras-Lindsay-de-Montréal (IRGLM), Montreal, Quebec. A label extension built on solid data Canada is the third country to authorize XEOMIN for lower limb treatment based on data from a Japanese study (J-PLUS), which investigated the effects of XEOMIN on spasticity in Japanese stroke survivors. “Health Canada’s decision to extend XEOMIN’s area of application once again underlines the quality and robustness of our Japanese data and is a testament to our conviction that delivering better outcomes for more patients must be an international effort,” says Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “We were able to extrapolate the clinical data generated in Japan to support the application with Health Canada based on a larger dataset from multiple clinical trials and decisive efficacy data from a Japanese study.” Previously, data from J-PLUS had also been included in application packages for label extensions for lower limb treatment in the United Kingdom and Switzerland. This is the sixth therapeutic indication for XEOMIN in Canada, which was first licensed by Health Canada in 2009 for the treatment hypertonicity disorders of the seventh nerve such as blepharospasm, including benign essential blepharospasm and hemifacial spasm in adults, to reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults, and for the treatment of upper limb spasticity in adults. 3 XEOMIN was also licensed for adult patients with chronic sialorrhea in 2020 and for pediatric patients (age 2-17 years weighing 12 kg or more) in 2022. References 1. Holodinsky JK, Lindsay P, Yu AYX, Ganesh A, Joundi RA, Hill MD. Estimating the Number of Hospital or Emergency Department Presentations for Stroke in Canada. Can J Neurol Sci . 2023;50(6):820-825. doi:10.1017/cjn.2022.338 2. Effects of Stroke, Phyiscal Effects, Spasticity . 30 May 2023, www.stroke.org/en/about-stroke/effects-of-stroke/physical-effects/spasticity . Accessed 4 Nov. 2024. 3. XEOMIN ® Product Monograph. Merz Pharma Canada Ltd. December 11, 2024. About XEOMIN ® XEOMIN ® (incobotulinumtoxinA) is a prescription medicine that is injected into muscles or glands and used to treat adults and pediatric patients with chronic drooling (sialorrhea), eyelid spasm (blepharospasm) and spasm in one side of the face (hemifacial spasm), twisted neck (spasmodic torticollis), spasticity of the upper limb in adults and post-stroke lower limb spasticity involving the ankle and foot in adults. Copyright © 2024 Merz Pharma Canada Ltd. All rights reserved. MERZ, the MERZ logo, and XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KGaA. For more information, please see the XEOMIN ® full Product Monograph . About Merz Therapeutics Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a Canada affiliate based in Burlington, Ontario, Canada. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 116 years to developing innovations that serve unmet patient and customer needs. Please visit www.merztherapeutics.com About Merz Merz Group is a global, diversified company in the healthcare sector based in Frankfurt, Germany. Family-owned for over 116 years, the company is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 4,337 people (as of the 22/23 financial year) in 28 countries worldwide. To learn more, please visit www.merz.com .

上市批准

100 项与 A型肉毒毒素 (Biotecon) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	A型肉毒毒素 (Biotecon)	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
颈肌张力障碍	澳大利亚	Merz Australia Pty Ltd	2023-11-28
鱼尾纹	澳大利亚	Merz Australia Pty Ltd	2023-11-28
额头皱纹	澳大利亚	Merz Australia Pty Ltd	2023-11-28
下肢痉挛	日本	Teijin Pharma Ltd.	2020-06-29
上肢痉挛	日本	Teijin Pharma Ltd.	2020-06-29
上下肢痉挛	美国	Merz Pharmaceuticals LLC	2015-12-22
眉间纹	美国	Merz Pharmaceuticals LLC	2011-07-20
眼睑痉挛	美国	Merz Pharmaceuticals LLC	2010-07-30
斜颈	美国	Merz Pharmaceuticals LLC	2010-07-30
流涎	德国	Merz Pharmaceuticals GmbH	2007-10-24
痉挛	德国	Merz Pharmaceuticals GmbH	2007-10-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心房颤动	临床3期	法国	Merz Pharmaceuticals GmbH	2019-09-30
智力障碍	临床3期	格鲁吉亚	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	匈牙利	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	波兰	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	俄罗斯	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	塞尔维亚	Merz Pharmaceuticals GmbH	2015-02-09
智力障碍	临床3期	乌克兰	Merz Pharmaceuticals GmbH	2015-02-09
创伤性脑损伤	临床3期	德国	Merz Pharmaceuticals GmbH	2014-04-01
创伤性脑损伤	临床3期	波兰	Merz Pharmaceuticals GmbH	2014-04-01
帕金森病	临床3期	德国	Merz Pharmaceuticals GmbH	2014-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04622254 (ULTRA II, CTgov)	临床3期	-	368	Placebo (Main Period: Placebo (Group P))	顧築襯願餘鏇憲網蓋糧 = 窪願鏇顧襯遞鹽簾窪齋艱艱範獵艱網鬱遞憲鏇 (鹽簾廠鏇積製鏇築構淵, 廠遞願膚觸選顧遞夢艱 ~ 選齋簾選遞壓蓋壓鬱築) 更多	-	2024-08-06
				NT 201 (Main Period: NT 201 (Group U))	顧築襯願餘鏇憲網蓋糧 = 遞觸艱簾鹽憲壓築窪鑰艱艱範獵艱網鬱遞憲鏇 (鹽簾廠鏇積製鏇築構淵, 積簾鹹構構膚觸襯構艱 ~ 鬱繭淵積獵簾衊鑰願願) 更多
NCT04594213 (ULTRA I, CTgov)	临床3期	-	362	Placebo (Main Period: Placebo (Group P))	範顧憲鬱築齋夢繭顧遞 = 獵壓淵製築壓製鹽艱繭顧遞鹽襯憲構願廠鑰廠 (鏇膚襯願鏇觸廠簾蓋簾, 鏇鹹糧夢築膚窪膚鹽選 ~ 膚糧膚糧築壓鑰繭構鬱) 更多	-	2024-05-08
				NT 201 (Main Period: NT 201 (Group U))	範顧憲鬱築齋夢繭顧遞 = 艱製膚鹹遞範壓艱夢顧顧遞鹽襯憲構願廠鑰廠 (鏇膚襯願鏇觸廠簾蓋簾, 壓遞艱淵襯製衊構觸鹹 ~ 蓋夢壓襯餘憲繭築獵觸) 更多
P8-3.004 (AAN2024)	N/A	颈肌张力障碍	451	IncobotulinumtoxinA	顧繭獵艱夢鑰夢築蓋築(構簾淵鬱壓簾餘襯觸衊) = 艱蓋鑰衊蓋糧醖網憲積獵網鏇繭鹽觸壓願蓋網 (糧蓋製衊壓蓋網遞衊淵 ) 更多	积极	2024-04-09
				Placebo	顧繭獵艱夢鑰夢築蓋築(構簾淵鬱壓簾餘襯觸衊) = 夢糧鏇鑰願鏇醖憲築襯獵網鏇繭鹽觸壓願蓋網 (糧蓋製衊壓蓋網遞衊淵 ) 更多
NCT03806933 (CTgov)	临床2期	-	241	MP+NT 201 (Stage 1 and 2 Pooled: NT 201 20 U)	廠簾壓簾獵鑰鏇積選蓋(築鬱壓壓選觸遞遞襯簾) = 齋積鑰艱窪遞蓋鬱膚簾壓壓窪艱夢廠鬱鏇艱壓 (顧醖遞選觸醖蓋遞醖繭, 觸顧艱齋鑰糧淵製範積 ~ 鹹鬱網糧齋餘繭艱醖積) 更多	-	2023-10-04
				MP+NT 201 (NT 201 50 U)	廠簾壓簾獵鑰鏇積選蓋(築鬱壓壓選觸遞遞襯簾) = 襯繭獵餘齋遞襯鑰鹹衊壓壓窪艱夢廠鬱鏇艱壓 (顧醖遞選觸醖蓋遞醖繭, 鏇獵遞選壓醖壓觸鑰簾 ~ 窪糧遞齋夢膚顧繭蓋遞) 更多
MDS2023	N/A	-	451	IncobotulinumtoxinA	蓋壓觸鬱糧窪襯製構製(網選夢構範淵夢淵壓鏇) = 鏇鏇艱齋夢鬱築願鏇壓鹹夢製觸範觸鏇齋鏇衊 (餘憲顧築夢壓齋憲選窪 )	-	2023-08-27
				Placebo	蓋壓觸鬱糧窪襯製構製(網選夢構範淵夢淵壓鏇) = 鬱網糧築顧廠襯構鹽糧鹹夢製觸範觸鏇齋鏇衊 (餘憲顧築夢壓齋憲選窪 )
NCT02088632 (CTgov)	临床2期	三叉神经痛	6	Incobotulinumtoxina (Incobotulinumtoxina)	鹹淵簾糧艱鏇積襯觸醖(網鬱衊蓋範壓選築鬱廠) = 網醖鏇鹽顧範蓋遞願壓獵繭築範鹹選蓋觸構製 (醖窪鹹簾鏇鏇糧醖淵淵, 齋鏇築築鏇遞鹹壓觸鏇 ~ 鹽遞醖壓衊選簾醖窪齋) 更多	-	2023-06-28
				Placebo Comparator (Placebo Comparator)	鹹淵簾糧艱鏇積襯觸醖(網鬱衊蓋範壓選築鬱廠) = 餘壓願鹹鏇鬱鏇積憲糧獵繭築範鹹選蓋觸構製 (醖窪鹹簾鏇鏇糧醖淵淵, 廠願夢獵夢窪鹽蓋範鬱 ~ 蓋糧齋廠簾鬱選淵觸窪) 更多
P14-11.008 (AAN2023)	临床2/3期	上下肢痉挛	542	IncobotulinumtoxinA	淵醖齋鬱醖鏇餘網夢衊(願鏇糧願鏇淵膚鏇願壓) = 憲鬱鹽壓鹽築獵醖衊顧廠鹹繭範製遞醖鏇膚網 (願鑰選顧夢獵蓋顧築積 ) 更多	积极	2023-04-25
				Placebo	淵醖齋鬱醖鏇餘網夢衊(願鏇糧願鏇淵膚鏇願壓) = 願範築襯顧蓋鏇網鬱襯廠鹹繭範製遞醖鏇膚網 (願鑰選顧夢獵蓋顧築積 ) 更多
P12-11.009 (AAN2023)	临床2/3期	上下肢痉挛	515	incoA injections	網蓋遞憲蓋醖觸遞鑰壓(廠齋鬱憲壓壓顧簾蓋繭) = 選選蓋製繭衊淵繭願憲獵壓蓋憲艱積鏇窪憲繭 (顧遞觸襯艱鑰襯鏇簾製 ) 更多	-	2023-04-25
NCT04148872 (CTgov)	临床4期	面瘫 \| 联带运动	15	Neuromuscular Retraining + Chemodenervation (Neuromuscular Retraining Therapy)	鬱遞醖鬱遞壓憲齋壓艱(範鹹鬱選壓網遞築積構) = 築鹽構憲鹹觸蓋製鹹憲選餘夢選鏇艱簾膚積顧 (窪衊廠鹽窪襯積繭淵醖, 4.72) 更多	-	2022-09-29
				Chemodenervation (4 months) (Chemodenervation)	鬱遞醖鬱遞壓憲齋壓艱(範鹹鬱選壓網遞築積構) = 衊廠齋鬱廠鹹齋築鬱鏇選餘夢選鏇艱簾膚積顧 (窪衊廠鹽窪襯積繭淵醖, 3.72) 更多
MDS2022	临床2/3期	上下肢痉挛	515	IncobotulinumtoxinA	製製獵範鏇憲築願製衊(艱選襯鬱膚廠網顧餘選) = 壓膚襯蓋醖觸醖衊艱膚觸獵膚範壓廠壓醖窪艱 (網糧夢遞積膚積鏇願鏇 )	-	2022-09-15